U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07950501) titled 'DOTA-1: Single-Fraction MR-guided Stereotactic Ablative Radiotherapy for Localized Prostate Cancer' on Nov. 10.

Brief Summary: This single-center, single-arm phase I/II pilot study evaluates the safety and feasibility of single-fraction stereotactic body radiotherapy (SBRT) with a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) in men with localized prostate cancer.

Ten participants with very low-, low-, or favorable intermediate-risk prostate adenocarcinoma and an MRI-visible DIL (PI-RADS 4-5) will be enrolled. After hydrogel rectal spacer insertion, patients receive MR-guided SBRT on an MR-Linac in one f...